The Triglyceride/Glucose Index and SGLT-2 Inhibitors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

55 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-10

Study Completion Date

2024-01-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was designed to evaluate the change in triglyceride glucose index, one of the atherosclerotic markers, in patients with type 2 DM followed in the Internal Medicine Clinic of Samsun University, Samsun Training, and Research Hospital.

Methods: The data of the patients who were followed up for at least 3 months by making a retrospective file review will be recorded and analyzed. It is planned to start the study following the ethics committee's approval.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Blood Sample Measurements and Physical Activity Levels in Type II Diabetes and/or COVID-19

NCT04695158

Covid19 Diabetes Mellitus, Type 2

UNKNOWN

Relations Between Atherogenic Index of Plasma-Glucose Metabolism

NCT02977598

Diabetes Mellitus Risk

COMPLETED

Association of Triglyceride Glucose Index and HOMA IR as Predictors of Vascular Complications of DM Type 2

NCT05695651

Type 2 Diabetes Mellitus

UNKNOWN

Triglyceride-Glucose Index in Diabetic Nephropathy in Type 2diaberes Mellitus Patients

NCT05602532

Diabetes Mellitus, Type 2

UNKNOWN

The Effect of SGLT2 Inhibitors on Cognitive Functions and BDNF Levels in Patients With Type 2 Diabetes

NCT05341388

Type2 Diabetes Cognitive Impairment

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The data of all patients who applied to Samsun Training and Research Hospital Internal Medicine outpatient clinic for 12 months in 2022 and were started on SGLT-2 inhibitor will be examined. According to the inclusion and exclusion criteria stated below, the patients will be evaluated and the data of the patients admitted to the study will be analyzed. The triglyceride glucose index of the patients before starting the SGLT-2 injection and the trig/glucose index at the end of 3 months of treatment will be calculated by the researchers using the data in the system. No additional blood tests or laboratory analyses will be performed on the patients. Triglyceride, glucose, and glycosylated hemoglobin values were checked at the beginning of the treatment and at the 3rd-month follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Disease Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Type 2 diabetic patients using SGLT-2 inhibitors

The data of all patients who applied to Samsun Training and Research Hospital Internal Medicine outpatient clinic for 12 months in 2022 and were started on SGLT-2 inhibitor will be examined. According to the inclusion and exclusion criteria, the patients will be evaluated and the data of the patients admitted to the study will be analyzed. The triglyceride glucose index of the patients before starting the SGLT-2 treatment and the triglyceride glucose index at the end of 3 months of treatment will be calculated by the researchers using the data in the system. No additional blood tests or laboratory analyses will be performed on the patients.

SGLT-2 inhibitors

Intervention Type OTHER

This study is an observational study. It is not planned to do an interventional activity.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SGLT-2 inhibitors

This study is an observational study. It is not planned to do an interventional activity.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 DM
* Age \>18 years old
* Dapagliflozin 10 mg or empagliflozin 10 mg or 25 mg
* 3 months follow-up period

Exclusion Criteria

* Type 1 diabetes
* Gestational diabetes
* Age \< 18 years old
* Insufficient or missed laboratory test results
* Medical treatment for dyslipidemia
* Hypothyroidism

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No